NCT00937872 is a Phase 1 clinical trial of 250 mg SRT2104 Suspension in Diabetes Mellitus, Type 2, sponsored by Sirtris, a GSK Company.

Who is sponsoring NCT00937872?

NCT00937872 is sponsored by Sirtris, a GSK Company.

What drugs are being tested in NCT00937872?

Interventions in NCT00937872: 250 mg SRT2104 Suspension, Carbon-14 radio-labeled SRT2104.

What condition does NCT00937872 study?

NCT00937872 studies Diabetes Mellitus, Type 2.

Is NCT00937872 still recruiting?

NCT00937872 is currently completed. Last updated 5 June 2017.

Last reviewed 2017-06-05 · How we verify

NCT00937872

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

Completed Phase 1 Last updated 5 June 2017

What this trial tests

Phase 1 trial testing 250 mg SRT2104 Suspension in Diabetes Mellitus, Type 2 in 9 participants. Completed in 22 December 2008.

Timeline

22 November 2008

Primary endpoint
22 December 2008

22 December 2008

Quick facts

Lead sponsor	Sirtris, a GSK Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	9
Start date	22 November 2008
Primary completion	22 December 2008
Estimated completion	22 December 2008
Sites	1 location across United Kingdom

Drugs / interventions tested

250 mg SRT2104 Suspension — full drug profile →
Carbon-14 radio-labeled SRT2104 — full drug profile →

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Sirtris, a GSK Company — full company profile →

Who can join

Adults 18 to 65, male only, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine the absolute bioavailability of SRT2104 as a 250 mg suspension, and to define the intravenous pharmacokinetics of SRT2104. The secondary objective of this study is to assess the potential systemic metabolite burden of SRT2104, and to provide plasma and urine samples for subsequent metabolite profiling and identification.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging roles of SIRT1 in fatty liver diseases.
Ding RB, Bao J, Deng CX. · · 2017 · cited 275× · PMID 28808418 · DOI 10.7150/ijbs.19370
Oxidative stress and epigenetic regulation in ageing and age-related diseases.
Cencioni C, Spallotta F, Martelli F, Valente S, et al · · 2013 · cited 137× · PMID 23989608 · DOI 10.3390/ijms140917643
Emerging roles of SIRT1 activator, SRT2104, in disease treatment.
Chang N, Li J, Lin S, Zhang J, et al · · 2024 · cited 49× · PMID 38448466 · DOI 10.1038/s41598-024-55923-8
Quantifying Competition among Mitochondrial Protein Acylation Events Induced by Ethanol Metabolism.
Ali HR, Assiri MA, Harris PS, Michel CR, et al · · 2019 · cited 21× · PMID 30644754 · DOI 10.1021/acs.jproteome.8b00800
The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1.
Fledderus J, Vanchin B, Rots MG, Krenning G. · · 2021 · cited 19× · PMID 33562658 · DOI 10.3390/jpm11020103
Roles of Sirtuins in Hearing Protection.
Koo C, Richter CP, Tan X. · · 2024 · cited 3× · PMID 39204103 · DOI 10.3390/ph17080998
Targeting both ferroptosis and pyroptosis may represent potential therapies for acute liver failure.
Xing ZY, Zhang CJ, Liu LJ. · · 2024 · cited 2× · PMID 39351426 · DOI 10.3748/wjg.v30.i33.3791

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Sirtris, a GSK Company trials

Trials by the same sponsor.

NCT01702493 — A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers · Phase 1 · completed
NCT01453491 — A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With U · Phase 1 · completed
NCT01416376 — Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation · Phase 1 · completed
NCT01340911 — A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases · Phase 1 · completed
NCT01262911 — Effect of SRT2379 on Endotoxin-Induced Inflammation · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00937872 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sirtris, a GSK Company
Last refreshed: 5 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00937872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing